I am taking Ozempic (semaglutide) for weight loss; when should I expect to see results and how frequently should I schedule follow‑up visits?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

When to Expect Weight Loss Results with Ozempic

Most patients begin seeing measurable weight loss within 4–12 weeks of starting Ozempic (semaglutide), with progressive weight reduction continuing through 6–12 months as the dose is titrated upward. 1, 2, 3, 4


Timeline for Weight Loss Results

Early Response (4–12 Weeks)

  • At 12 weeks on low-dose semaglutide (0.25–1 mg weekly), non-diabetic patients achieve an average weight loss of 5.91 kg (approximately 6.15% of baseline body weight). 3
  • This early weight loss is clinically meaningful and predicts continued success with dose escalation. 1, 2

Intermediate Response (3–6 Months)

  • By 3 months, patients on therapeutic doses (1.7–2.4 mg weekly) lose an average of 6.7 kg (5.9% of baseline weight). 4
  • By 6 months, mean weight loss reaches 12.3 kg (10.9% of baseline weight), with 87.3% of patients achieving ≥5% weight loss and 54.9% achieving ≥10% weight loss. 4, 5

Peak Response (12–24 Months)

  • At 12 months, patients achieve 17.6% mean weight loss, with 43.3% reaching ≥20% weight reduction. 5
  • Weight loss plateaus around 18–24 months at approximately 20.3–20.4% of baseline weight, with over 50% of patients maintaining ≥20% weight loss. 5
  • The landmark STEP 1 trial demonstrated 14.9% mean weight loss at 68 weeks with semaglutide 2.4 mg weekly, compared to 2.4% with placebo. 1, 6, 7

Critical Efficacy Assessment Point

If you have not lost at least 5% of your baseline body weight after 3 months at therapeutic dose, the medication should be discontinued, as early non-responders are unlikely to benefit from continued therapy. 1, 2


Follow-Up Schedule

During Dose Titration (First 16 Weeks)

  • Follow up every 4 weeks during the initial titration phase to monitor gastrointestinal tolerance, assess early weight loss progress, and adjust dosing. 1, 2
  • Semaglutide requires gradual dose escalation over 16 weeks: starting at 0.25 mg weekly for 4 weeks, then 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, and finally reaching the maintenance dose of 2.4 mg weekly. 1, 2

After Reaching Maintenance Dose

  • Follow up every 3 months (quarterly) to evaluate continued weight loss progress, cardiovascular risk factors, medication adherence, and adverse effects. 1, 2
  • Monitor weight as a percentage of baseline, blood pressure (as antihypertensive medications may need adjustment), and signs of gallbladder disease or pancreatitis. 1, 2, 8

Critical Decision Point at 12–16 Weeks

  • Formal efficacy assessment at 12–16 weeks on the maximum tolerated therapeutic dose is essential. 1, 2
  • If weight loss is <5% after 3 months at therapeutic dose, discontinue semaglutide and consider alternative approaches (such as tirzepatide, which achieves superior 20.9% weight loss). 1, 2

Factors Affecting Weight Loss Response

Diabetes Status

  • Weight loss is lower in patients with type 2 diabetes (4–6.2%) compared to non-diabetic patients (6.1–17.4%). 1
  • In real-world data, diabetic patients achieved only 3.9% weight loss at 3 months versus 6.3% in non-diabetics, and 7.2% at 6 months versus 11.8% in non-diabetics. 4

Lifestyle Modifications

  • Semaglutide must be combined with a reduced-calorie diet (500-kcal deficit) and minimum 150 minutes per week of physical activity for optimal results. 1, 2
  • Medication alone without lifestyle modification produces suboptimal weight loss. 1, 2

Long-Term Considerations

Lifelong Treatment Required

  • Semaglutide requires lifelong use for sustained weight loss. After cessation, significant weight regain occurs, with 11.6% of lost weight regained after 52 weeks. 1
  • Discontinuation results in loss of cardiometabolic improvements, including beneficial effects on blood pressure, lipid profiles, and glucose metabolism. 1

Cost Planning

  • The average wholesale price is approximately $1,557–$1,619 per 30-day supply, requiring long-term financial planning and insurance authorization. 1

Common Pitfalls to Avoid

  • Do not wait longer than 3–4 months to assess initial treatment response, as early non-responders are unlikely to benefit from continued therapy. 1, 2
  • Do not delay follow-up beyond 3 months in the maintenance phase, as this may miss treatment failure or adverse effects. 1, 2
  • Do not expect immediate results—weight loss is progressive and requires patience through the 16-week titration period. 1, 2
  • Do not discontinue lifestyle modifications once weight loss begins, as medication works synergistically with diet and exercise. 1, 2

References

Guideline

Pharmacological Management of Obesity

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

GLP-1 Receptor Agonists for Weight Loss

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Efficacy and Safety of Semaglutide in Weight Loss of Non-diabetic People.

Endocrine, metabolic & immune disorders drug targets, 2024

Research

Semaglutide for the treatment of obesity.

Trends in cardiovascular medicine, 2023

Research

Once-Weekly Semaglutide in Adults with Overweight or Obesity.

The New England journal of medicine, 2021

Guideline

Non-Weight-Related Benefits of GLP-1 Receptor Agonists

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.